



Press release from Emotra AB (publ)

Göteborg, May 9, 2019

EDOR® Test Identifies Patients with a Higher Risk of Depression Relapse

Emotra has previously announced that new research results have indicated new application areas for Emotra's method, EDOR. These areas open new possibilities for widening the method's use in clinical practice. We can now reveal that the application in question concerns the fact that hyporeactive patients run a higher risk of depression relapse than normally reactive patients.

Emotra was presented with material from a study conducted by researchers at a psychiatric hospital and has now carried out further independent analyses. Our opinion is that the preliminary results have been confirmed. Emotra has submitted a patent application to the Swedish patent office, PRV, to protect this new application. The study results show that depressed hyporeactive patients run a significantly higher risk of sliding back into depression than normally reactive patients do.

Access to biomarkers that can help identify a risk of relapse is considered by today's psychiatrists to be one of their greatest and most urgent needs. It is estimated that half of all patients who recover from their first depression will suffer one or two more episodes in their lives, and that 80 percent of patients who have experienced two episodes will suffer a new relapse. This affects a large number of patients and the cost to society is very high. In Sweden alone, the cost of psychiatric disorders is estimated to be about 75 billion SEK per year, with depression accounting for the lion's share of this, about 35 billion SEK. These high yearly costs are due to absence from work due to illness and lost productivity, but are also largely due to the fact that depressions are recurrent.

The group with a higher risk for depression relapse is the same group, hyporeactive depressed patients, that shows a higher risk of suicide and suicide attempts. However, the clinical numbers differ considerably. Our experience from marketing discussions is that each hospital unit experiences a low number of suicides per year. On the other hand, specialised psychiatric clinics face, on a daily basis, the decision of whether or not to continue to medicate a depressed patient. In those cases, early diagnosis can provide useful information for tailoring the care given, which can lead to lower costs and increased patient safety.

This discovery is very important. If a simple test can help healthcare providers identify a patient group with an increased risk of depression relapse and then tailor their care to

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company's method, EDOR®, is a proprietary and objective psychophysiological test for detecting if patients suffering from depression are hyporeactive.



prevent such a relapse, this will also reduce the risk of these patients taking their own lives. This is especially true for patients that suffer a first depression.

Daniel Poté, Emotra's CEO, says:

"The discovery that EDOR can identify those patients who risk relapsing is enormously important for Emotra. We believe it will be easier to point out the practical consequences of this new application of the EDOR Test. At the same time, it underscores the importance of hyporeactivity as a risk marker. Early diagnosis normally leads to lower risk and better patient care results. EDOR presents a good opportunity to focus on risk populations earlier and to a greater degree tailor the care of depressed patients, thereby also lowering the risk of suicide. Since this a new indication area, we will be seeking new collaboration partners and supporting scientific studies. Partnerships are very important in this case, since we are dealing with new indications and knowledge areas for the company."

Emotra will start to compile a portfolio of relapse results in various clinical situations in parallel with our ongoing marketing work. We plan to carry out more studies and also expect to strengthen the case for hyporeactivity as a biomarker. Our foremost reason for carrying out these studies is that decision-makers often request documentation from several independent centres that point in the same direction.

For further information about Emotra, please contact:

Daniel Poté, CEO, telephone: +46-732 34 41 93, E-mail: daniel@emotra.se

This information is the type of information that Emotra AB is legally obliged to publish in accordance with the EU market abuse regulation. This information was submitted for publication on May 9, 2019, under the above contact's supervision.

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company's method, EDOR®, is a proprietary and objective psychophysiological test for detecting if patients suffering from depression are hyporeactive.